Melasma. Chloasma
Conditions
Interventions
Approving the Januluma whitening cream on patient with moderate to severe melasma (single arm study ).
Treatment - Drugs
Approving the Januluma whitening cream on patient with moderate to severe melasma (single arm study )
Sponsors
Jarfandishan-e Navid-e Salamat (Janus) knowledge-based company
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion : Case of moderate to severe melasma (MGSC>2); age range 18-50 (men or women); signed informed consent voluntarily and knowingly Exclusion :pregnancy or lactation? use of systemic corticosteroid, isotretinoin within 28 days prior to the study; use any light sensitive drug within 3 months prior to the study? Active skin disease at test area: rosacea, atrophy, acne, eczema; Use of topical lightening products like AHA ,BHA and retinoid component within 21 days prior to the study; Documented allergies to components of Januluma cream? Use of contraceptive or any hormonal drugs? History of laser treatment or dermabrasion or deep facial peels within the past 3 months
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified melasma severity index. Timepoint: Before intervention, one month later, two month after intervention. Method of measurement: mMASI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin pH. Timepoint: before and after 4and 8 weeks. Method of measurement: MPA 580.;Skin sebum. Timepoint: Before and after 4and 8 weeks. Method of measurement: MPA 580.;Skin melanin and erythem. Timepoint: before and after 4 and 8 weeks. Method of measurement: MPA 580.;TEWL. Timepoint: before and after 4 and 8 weeks. Method of measurement: MPA 580.;Size and value of skin spot. Timepoint: before and after 4 and 8 weeks. Method of measurement: Visioface. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaman Ahmad Nasrollahi
Center For Research And Training In Skin Diseases And Leprosy
Outcome results
None listed